Actively Recruiting
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Led by Swiss GO Trial Group · Updated on 2026-05-05
60
Participants Needed
7
Research Sites
178 weeks
Total Duration
On this page
Sponsors
S
Swiss GO Trial Group
Lead Sponsor
T
Tumor Profiler Center Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
CONDITIONS
Official Title
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed epithelial ovarian cancer, peritoneal, fallopian tube adenocarcinoma, or carcinosarcoma patients suspected of FIGO Stage III or IV
- No urgent need for systemic or surgical treatment at diagnosis and for 2 weeks after
- Planned candidate for interval debulking surgery after 2 treatment cycles
- Able and willing to attend visits and understand trial procedures
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Provided written informed consent according to legal and regulatory requirements
You will not qualify if you...
- Liver enzyme levels more than twice the normal range (ASAT > 68 U/l, ALAT > 82 U/l, GGT > 80 U/l)
- Elevated creatinine above twice the normal range (>120 mmol/l)
- ECOG performance status 3 or higher
- Pregnant or breastfeeding women
- Any other malignancy in the past 5 years affecting prognosis
- Inability to swallow tablets
- Currently participating in another clinical trial for the same condition
- Any serious medical, psychiatric, psychological, family, or geographical condition that may interfere with the study or compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Kantonsspital Baden AG
Baden, Canton of Aargau, Switzerland, 5404
Actively Recruiting
2
Universitätsspital Basel
Basel, Canton of Basel-City, Switzerland, 4031
Actively Recruiting
3
HOCH Health Ostschweiz Kantonsspital St.Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland, 9007
Actively Recruiting
4
Thurgau AG Frauenfeld / Münsterlingen
Frauenfeld, Thurgau, Switzerland, 8500
Actively Recruiting
5
Inselspital Bern (University Hospital for Medical Oncology)
Bern, Switzerland, 3010
Actively Recruiting
6
HFR-Fribourg- Hopital Cantonal
Fribourg, Switzerland, 1708
Actively Recruiting
7
University Hospital Zurich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
M
Maren S Vogel, PhD
CONTACT
T
Team Swiss GO Trial Group
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here